Gottlieb: Senate HELP’s 180-Day Generic Exclusivity Fix Falls Short

By Donna Haseley / June 7, 2019 at 2:18 PM
Former FDA Commissioner Scott Gottlieb says the most aggressive piece of the Senate health committee’s drug-pricing package -- the 180-day generic marketing exclusivity fix -- falls short. Instead of placing new limits on exclusivity, he says, lawmakers should give generic drug makers even more exclusivity. Current law gives the first generic to successfully challenge a brand patent 180 days on the market without other generic competitors. That way the first generic can keep prices high for half of a year...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.